PubRank

Melvin E Andersen

Author PubWeight™ 158.88‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Toxicity testing in the 21st century: implications for human health risk assessment. Risk Anal 2008 5.57
2 Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol 2013 3.00
3 Inhaled carbon nanotubes reach the subpleural tissue in mice. Nat Nanotechnol 2009 2.78
4 Reactive oxygen species as a signal in glucose-stimulated insulin secretion. Diabetes 2007 2.59
5 Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. Toxicol Sci 2011 2.03
6 A comprehensive statistical analysis of predicting in vivo hazard using high-throughput in vitro screening. Toxicol Sci 2012 1.81
7 ROS signaling, oxidative stress and Nrf2 in pancreatic beta-cell function. Toxicol Appl Pharmacol 2009 1.63
8 Low-level arsenic impairs glucose-stimulated insulin secretion in pancreatic beta cells: involvement of cellular adaptive response to oxidative stress. Environ Health Perspect 2010 1.47
9 Organotypic liver culture models: meeting current challenges in toxicity testing. Crit Rev Toxicol 2012 1.46
10 Applying mode-of-action and pharmacokinetic considerations in contemporary cancer risk assessments: an example with trichloroethylene. Crit Rev Toxicol 2004 1.45
11 Physiological modeling of inhalation kinetics of octamethylcyclotetrasiloxane in humans during rest and exercise. Toxicol Sci 2003 1.44
12 Application of biologically based computer modeling to simple or complex mixtures. Environ Health Perspect 2002 1.42
13 Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. Toxicol Sci 2010 1.30
14 A systems biology perspective on Nrf2-mediated antioxidant response. Toxicol Appl Pharmacol 2009 1.25
15 A deterministic map of Waddington's epigenetic landscape for cell fate specification. BMC Syst Biol 2011 1.21
16 Ultrasensitive response motifs: basic amplifiers in molecular signalling networks. Open Biol 2013 1.16
17 Dose-dependent transitions in Nrf2-mediated adaptive response and related stress responses to hypochlorous acid in mouse macrophages. Toxicol Appl Pharmacol 2009 1.15
18 Is the relationship between prenatal exposure to PCB-153 and decreased birth weight attributable to pharmacokinetics? Environ Health Perspect 2013 1.14
19 Single cell analysis of switch-like induction of CYP1A1 in liver cell lines. Toxicol Sci 2004 1.13
20 The need for a new toxicity testing and risk analysis paradigm to implement REACH or any other large scale testing initiative. Arch Toxicol 2007 1.11
21 Adipose deficiency of Nrf2 in ob/ob mice results in severe metabolic syndrome. Diabetes 2012 1.10
22 Incorporating new technologies into toxicity testing and risk assessment: moving from 21st century vision to a data-driven framework. Toxicol Sci 2013 1.10
23 New directions in toxicity testing. Annu Rev Public Health 2011 1.09
24 Toxicity testing in the 21 century: defining new risk assessment approaches based on perturbation of intracellular toxicity pathways. PLoS One 2011 1.09
25 Induction of CYP1A1 in primary rat hepatocytes by 3,3',4,4',5-pentachlorobiphenyl: evidence for a switch circuit element. Toxicol Sci 2004 1.08
26 Dose-dependent transitions in mechanisms of toxicity: case studies. Toxicol Appl Pharmacol 2004 1.08
27 Long isoforms of NRF1 contribute to arsenic-induced antioxidant response in human keratinocytes. Environ Health Perspect 2010 1.07
28 Quantitative interpretation of human biomonitoring data. Toxicol Appl Pharmacol 2008 1.07
29 Dose response relationship in anti-stress gene regulatory networks. PLoS Comput Biol 2006 1.07
30 Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation. Toxicol Sci 2007 1.07
31 Linear low-dose extrapolation for noncancer heath effects is the exception, not the rule. Crit Rev Toxicol 2011 1.07
32 Nuclear factor erythroid-derived factor 2-related factor 2 regulates transcription of CCAAT/enhancer-binding protein β during adipogenesis. Free Radic Biol Med 2011 1.07
33 t4 workshop report: Pathways of Toxicity. ALTEX 2013 1.06
34 Relative impact of incorporating pharmacokinetics on predicting in vivo hazard and mode of action from high-throughput in vitro toxicity assays. Toxicol Sci 2013 1.03
35 Application of transcriptional benchmark dose values in quantitative cancer and noncancer risk assessment. Toxicol Sci 2010 1.03
36 Quantitative analyses and transcriptomic profiling of circulating messenger RNAs as biomarkers of rat liver injury. Hepatology 2010 1.03
37 In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI. J Pharmacokinet Pharmacodyn 2012 1.02
38 Prolonged inorganic arsenite exposure suppresses insulin-stimulated AKT S473 phosphorylation and glucose uptake in 3T3-L1 adipocytes: involvement of the adaptive antioxidant response. Biochem Biophys Res Commun 2011 1.02
39 Activation of Nrf2-mediated oxidative stress response in macrophages by hypochlorous acid. Toxicol Appl Pharmacol 2007 1.02
40 Development of PBPK models for PFOA and PFOS for human pregnancy and lactation life stages. J Toxicol Environ Health A 2013 1.00
41 A method to integrate benchmark dose estimates with genomic data to assess the functional effects of chemical exposure. Toxicol Sci 2007 1.00
42 Analysis of manganese tracer kinetics and target tissue dosimetry in monkeys and humans with multi-route physiologically based pharmacokinetic models. Toxicol Sci 2010 0.99
43 Non-monotonic dose-response relationship in steroid hormone receptor-mediated gene expression. J Mol Endocrinol 2007 0.99
44 In silico toxicology: simulating interaction thresholds for human exposure to mixtures of trichloroethylene, tetrachloroethylene, and 1,1,1-trichloroethane. Environ Health Perspect 2002 0.98
45 Application of pharmacokinetic data to the risk assessment of inhaled manganese. Neurotoxicology 2006 0.98
46 Temporal concordance between apical and transcriptional points of departure for chemical risk assessment. Toxicol Sci 2013 0.98
47 An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. J Pharmacol Exp Ther 2012 0.98
48 A mechanistic redefinition of adverse effects - a key step in the toxicity testing paradigm shift. ALTEX 2010 0.96
49 The use of Markov chain Monte Carlo uncertainty analysis to support a Public Health Goal for perchloroethylene. Regul Toxicol Pharmacol 2006 0.96
50 Time dependencies in perfluorooctylacids disposition in rat and monkeys: a kinetic analysis. Toxicol Lett 2007 0.95
51 Dose-dependent transitions in mechanisms of toxicity. Toxicol Appl Pharmacol 2004 0.95
52 Progestin receptor expression in the developing rat brain depends upon activation of estrogen receptor alpha and not estrogen receptor beta. Brain Res 2006 0.94
53 Pharmacokinetic modeling of disposition and time-course studies with [14C]atrazine. J Toxicol Environ Health A 2003 0.94
54 Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results. Crit Rev Toxicol 2012 0.93
55 Evidence that atrazine and diaminochlorotriazine inhibit the estrogen/progesterone induced surge of luteinizing hormone in female Sprague-Dawley rats without changing estrogen receptor action. Toxicol Sci 2004 0.93
56 Physiologically based pharmacokinetic modeling of fetal and neonatal manganese exposure in humans: describing manganese homeostasis during development. Toxicol Sci 2011 0.92
57 Detection and localization of an estrogen receptor beta splice variant protein (ERbeta2) in the adult female rat forebrain and midbrain regions. J Comp Neurol 2007 0.92
58 Integrating pathway-based transcriptomic data into quantitative chemical risk assessment: a five chemical case study. Mutat Res 2012 0.92
59 Assessing the relevance of in vitro measures of phthalate inhibition of steroidogenesis for in vivo response. Toxicol In Vitro 2009 0.91
60 Cross-regulations among NRFs and KEAP1 and effects of their silencing on arsenic-induced antioxidant response and cytotoxicity in human keratinocytes. Environ Health Perspect 2012 0.90
61 Regional induction of CYP1A1 in rat liver following treatment with mixtures of PCB 126 and PCB 153. Toxicol Pathol 2004 0.90
62 A framework for the next generation of risk science. Environ Health Perspect 2014 0.89
63 Defining and modeling known adverse outcome pathways: Domoic acid and neuronal signaling as a case study. Environ Toxicol Chem 2011 0.89
64 A bistable switch underlying B-cell differentiation and its disruption by the environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Sci 2010 0.88
65 Phase I to II cross-induction of xenobiotic metabolizing enzymes: a feedforward control mechanism for potential hormetic responses. Toxicol Appl Pharmacol 2009 0.88
66 Associations of Perfluoroalkyl Substances (PFAS) with Lower Birth Weight: An Evaluation of Potential Confounding by Glomerular Filtration Rate Using a Physiologically Based Pharmacokinetic Model (PBPK). Environ Health Perspect 2015 0.88
67 Identification of Nrf2-dependent airway epithelial adaptive response to proinflammatory oxidant-hypochlorous acid challenge by transcription profiling. Am J Physiol Lung Cell Mol Physiol 2007 0.87
68 Pharmacokinetic modeling of manganese in the rat IV: Assessing factors that contribute to brain accumulation during inhalation exposure. J Toxicol Environ Health A 2008 0.87
69 Closed-chamber inhalation pharmacokinetic studies with hexamethyldisiloxane in the rat. Inhal Toxicol 2003 0.86
70 Computational systems biology and dose-response modeling in relation to new directions in toxicity testing. J Toxicol Environ Health B Crit Rev 2010 0.86
71 Evaluation of potential toxicity from co-exposure to three CNS depressants (toluene, ethylbenzene, and xylene) under resting and working conditions using PBPK modeling. J Occup Environ Hyg 2005 0.86
72 Use of short-term transcriptional profiles to assess the long-term cancer-related safety of environmental and industrial chemicals. Toxicol Sci 2009 0.86
73 Hormesis and adaptive cellular control systems. Dose Response 2008 0.86
74 Accelerating the development of 21st-century toxicology: outcome of a Human Toxicology Project Consortium workshop. Toxicol Sci 2011 0.86
75 Genome-wide analysis of DNA methylation and gene expression changes in the mouse lung following subchronic arsenate exposure. Toxicol Sci 2010 0.86
76 Binary gene induction and protein expression in individual cells. Theor Biol Med Model 2006 0.86
77 Dose-response modeling of cytochrome p450 induction in rats by octamethylcyclotetrasiloxane. Toxicol Sci 2002 0.86
78 Association between arsenic suppression of adipogenesis and induction of CHOP10 via the endoplasmic reticulum stress response. Environ Health Perspect 2012 0.86
79 Characterization of the pharmacokinetics of gasoline using PBPK modeling with a complex mixtures chemical lumping approach. Inhal Toxicol 2003 0.85
80 Evaluating placental transfer and tissue concentrations of manganese in the pregnant rat and fetuses after inhalation exposures with a PBPK model. Toxicol Sci 2009 0.85
81 Use of a pharmacokinetic-driven computational fluid dynamics model to predict nasal extraction of hydrogen sulfide in rats and humans. Toxicol Sci 2006 0.85
82 Deficiency in the nuclear factor E2-related factor 2 renders pancreatic β-cells vulnerable to arsenic-induced cell damage. Toxicol Appl Pharmacol 2012 0.85
83 A physiologically based pharmacokinetic model for lactational transfer of PCB 153 with or without PCB 126 in mice. Arch Toxicol 2006 0.85
84 A dermatotoxicokinetic model of human exposures to jet fuel. Toxicol Sci 2006 0.85
85 Evaluation of placental and lactational pharmacokinetics of PFOA and PFOS in the pregnant, lactating, fetal and neonatal rat using a physiologically based pharmacokinetic model. Reprod Toxicol 2011 0.84
86 Evaluating transport of manganese from olfactory mucosa to striatum by pharmacokinetic modeling. Toxicol Sci 2007 0.84
87 A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment. Environ Health Perspect 2002 0.84
88 PBPK modeling of complex hydrocarbon mixtures: gasoline. Environ Toxicol Pharmacol 2004 0.84
89 Modeling drug- and chemical-induced hepatotoxicity with systems biology approaches. Front Physiol 2012 0.84
90 Identification of a novel hemoglobin adduct in Sprague Dawley rats exposed to atrazine. Chem Res Toxicol 2006 0.84
91 Derivation of an inhalation reference concentration based upon olfactory neuronal loss in male rats following subchronic acetaldehyde inhalation. Inhal Toxicol 2008 0.84
92 Stochastic modeling of B lymphocyte terminal differentiation and its suppression by dioxin. BMC Syst Biol 2010 0.83
93 t4 workshop report--lessons learned, challenges, and opportunities: the U.S. Endocrine Disruptor Screening Program. ALTEX 2013 0.83
94 Evaluation of physiologically based pharmacokinetic models in risk assessment: an example with perchloroethylene. Crit Rev Toxicol 2005 0.83
95 Application of a physiologically based pharmacokinetic model for isopropanol in the derivation of a reference dose and reference concentration. Regul Toxicol Pharmacol 2002 0.83
96 A biologically based dose-response model for dietary iodide and the hypothalamic-pituitary-thyroid axis in the adult rat: evaluation of iodide deficiency. Toxicol Sci 2008 0.83
97 Long-term stability of primary rat hepatocytes in micropatterned cocultures. J Biochem Mol Toxicol 2013 0.83
98 Regulatory role of KEAP1 and NRF2 in PPARγ expression and chemoresistance in human non-small-cell lung carcinoma cells. Free Radic Biol Med 2012 0.83
99 Divergent effects of sulforaphane on basal and glucose-stimulated insulin secretion in β-cells: role of reactive oxygen species and induction of endogenous antioxidants. Pharm Res 2013 0.83
100 In vitro metabolism of di(2-ethylhexyl) phthalate (DEHP) by various tissues and cytochrome P450s of human and rat. Toxicol In Vitro 2011 0.83
101 Incorporation of tissue reaction kinetics in a computational fluid dynamics model for nasal extraction of inhaled hydrogen sulfide in rats. Toxicol Sci 2005 0.82
102 Dermal absorption and penetration of jet fuel components in humans. Toxicol Lett 2006 0.82
103 Evaluation and prediction of pharmacokinetics of PFOA and PFOS in the monkey and human using a PBPK model. Regul Toxicol Pharmacol 2011 0.82
104 Development of an immunochemical detection method for atrazine-induced albumin adducts. Chem Res Toxicol 2007 0.82
105 PBTK modeling demonstrates contribution of dermal and inhalation exposure components to end-exhaled breath concentrations of naphthalene. Environ Health Perspect 2007 0.82
106 Molecular signaling network motifs provide a mechanistic basis for cellular threshold responses. Environ Health Perspect 2014 0.82
107 Isoniazid suppresses antioxidant response element activities and impairs adipogenesis in mouse and human preadipocytes. Toxicol Appl Pharmacol 2013 0.81
108 Bayesian estimation of pharmacokinetic and pharmacodynamic parameters in a mode-of-action-based cancer risk assessment for chloroform. Risk Anal 2007 0.81
109 Competitive inhibition of thyroidal uptake of dietary iodide by perchlorate does not describe perturbations in rat serum total T4 and TSH. Environ Health Perspect 2009 0.81
110 Comparison and evaluation of pharmacokinetics of PFOA and PFOS in the adult rat using a physiologically based pharmacokinetic model. Reprod Toxicol 2011 0.81
111 Pharmacokinetic modeling of manganese. I. Dose dependencies of uptake and elimination. J Toxicol Environ Health A 2007 0.81
112 Quantitative identification of atrazine and its chlorinated metabolites in plasma. J Anal Toxicol 2003 0.81
113 In vitro intestinal and hepatic metabolism of Di(2-ethylhexyl) phthalate (DEHP) in human and rat. Toxicol In Vitro 2013 0.81
114 Chemical mixture toxicology: from descriptive to mechanistic, and going on to in silico toxicology. Environ Toxicol Pharmacol 2004 0.81
115 Workshop overview: reassessment of the cancer risk of dichloromethane in humans. Toxicol Sci 2006 0.80
116 Toxicokinetics and physiologically based toxicokinetics in toxicology and risk assessment. J Toxicol Environ Health B Crit Rev 2003 0.80
117 Pharmacokinetic modeling of manganese. II. Hepatic processing after ingestion and inhalation. J Toxicol Environ Health A 2007 0.80
118 Dose-response modeling of etoposide-induced DNA damage response. Toxicol Sci 2013 0.80
119 Occupational exposure limits in the context of solvent mixtures, consumption of ethanol, and target tissue dose. Toxicol Ind Health 2004 0.80
120 A dose response study to assess effects after dietary administration of diisononyl phthalate (DINP) in gestation and lactation on male rat sexual development. Reprod Toxicol 2012 0.80
121 Lactational transfer of manganese in rats: predicting manganese tissue concentration in the dam and pups from inhalation exposure with a pharmacokinetic model. Toxicol Sci 2009 0.80
122 Update on a Pharmacokinetic-Centric Alternative Tier II Program for MMT-Part II: Physiologically Based Pharmacokinetic Modeling and Manganese Risk Assessment. J Toxicol 2012 0.80
123 Pharmacokinetic modeling of manganese. III. Physiological approaches accounting for background and tracer kinetics. J Toxicol Environ Health A 2007 0.79
124 Pollution trees: identifying similarities among complex pollutant mixtures in water and correlating them to mutagenicity. Environ Sci Technol 2012 0.79
125 Physiologically based pharmacokinetic modeling of styrene and styrene oxide respiratory-tract dosimetry in rodents and humans. Inhal Toxicol 2002 0.79
126 Oral absorption and oxidative metabolism of atrazine in rats evaluated by physiological modeling approaches. Toxicology 2007 0.79
127 Estimating constants for metabolism of atrazine in freshly isolated rat hepatocytes by kinetic modeling. Toxicol In Vitro 2006 0.79
128 On the incorporation of chemical-specific information in risk assessment. Toxicol Lett 2008 0.79
129 Kinetics of selected di-n-butyl phthalate metabolites and fetal testosterone following repeated and single administration in pregnant rats. Toxicology 2008 0.79
130 Toxicogenomics for transcription factor-governed molecular pathways: moving on to roles beyond classification and prediction. Arch Toxicol 2012 0.79
131 Modeling of human dermal absorption of octamethylcyclotetrasiloxane (D(4)) and decamethylcyclopentasiloxane (D(5)). Toxicol Sci 2007 0.79
132 Ethyl acrylate risk assessment with a hybrid computational fluid dynamics and physiologically based nasal dosimetry model. Toxicol Sci 2004 0.79
133 CNC-bZIP protein Nrf1-dependent regulation of glucose-stimulated insulin secretion. Antioxid Redox Signal 2015 0.78
134 Effects of endogenous formaldehyde in nasal tissues on inhaled formaldehyde dosimetry predictions in the rat, monkey, and human nasal passages. Toxicol Sci 2014 0.78
135 Physiologically based pharmacokinetic/toxicokinetic modeling. Methods Mol Biol 2012 0.78
136 Assessing dose-dependent differences in DNA-damage, p53 response and genotoxicity for quercetin and curcumin. Toxicol In Vitro 2013 0.78
137 Disposition of diiosononyl phthalate and its effects on sexual development of the male fetus following repeated dosing in pregnant rats. Reprod Toxicol 2012 0.78
138 Update on a Pharmacokinetic-Centric Alternative Tier II Program for MMT-Part I: Program Implementation and Lessons Learned. J Toxicol 2012 0.78
139 All-or-none suppression of B cell terminal differentiation by environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Appl Pharmacol 2013 0.78
140 Organic extract contaminants from drinking water activate Nrf2-mediated antioxidant response in a human cell line. Environ Sci Technol 2013 0.77
141 Manganese tissue dosimetry in rats and monkeys: accounting for dietary and inhaled Mn with physiologically based pharmacokinetic modeling. Toxicol Sci 2008 0.77
142 A hybrid CFD-PBPK model for naphthalene in rat and human with IVIVE for nasal tissue metabolism and cross-species dosimetry. Inhal Toxicol 2014 0.77
143 Stochastic simulation of hepatic preneoplastic foci development for four chlorobenzene congeners in a medium-term bioassay. Toxicol Sci 2003 0.77
144 Development of 3D dynamic flow model of human liver and its application to prediction of metabolic clearance of 7-ethoxycoumarin. Tissue Eng Part C Methods 2014 0.77
145 Assessing kinetic determinants for metabolism and oral uptake of octamethylcyclotetrasiloxane (D4) from inhalation chamber studies. Inhal Toxicol 2008 0.77
146 The Next Generation of Risk Assessment Multi-Year Study-Highlights of Findings, Applications to Risk Assessment, and Future Directions. Environ Health Perspect 2016 0.77
147 Keap1 silencing boosts lipopolysaccharide-induced transcription of interleukin 6 via activation of nuclear factor κB in macrophages. Toxicol Appl Pharmacol 2013 0.77
148 Tissue exposures to free and glucuronidated monobutylyphthalate in the pregnant and fetal rat following exposure to di-n-butylphthalate: evaluation with a PBPK model. Toxicol Sci 2008 0.77
149 Measurement of tumor-associated mutations in the nasal mucosa of rats exposed to varying doses of formaldehyde. Regul Toxicol Pharmacol 2010 0.77
150 Comment on M.V. Evans and J.C. Caldwell: evaluation of two different metabolic hypotheses for dichloromethane toxicity using physiologically based pharmacokinetic modeling of in vivo gas uptake data exposure in female B6C3F1 mice, Toxicol. Appl. Pharmacol., 244, 280-290, 2010. Toxicol Appl Pharmacol 2010 0.77
151 Combined exposure to 3-chloro-4-dichloromethyl-5-hydroxy-2(5H)-furanone and microsytin-LR increases genotoxicity in Chinese hamster ovary cells through oxidative stress. Environ Sci Technol 2013 0.77
152 Iodoacetic acid activates Nrf2-mediated antioxidant response in vitro and in vivo. Environ Sci Technol 2014 0.76
153 Hepatic sequestration of chlordecone and hexafluoroacetone evaluated by pharmacokinetic modeling. Toxicology 2007 0.76
154 3-chlorotyrosine and 3,5-dichlorotyrosine as biomarkers of respiratory tract exposure to chlorine gas. J Anal Toxicol 2008 0.76
155 Bioactivation and toxicity of acetaminophen in a rat hepatocyte micropatterned coculture system. J Biochem Mol Toxicol 2013 0.76
156 A physiologically based pharmacokinetic model for acrylamide and its metabolite, glycidamide, in the rat. J Toxicol Environ Health A 2003 0.76
157 Inhalation dosimetry of hexamethylene diisocyanate vapor in the rat and human respiratory tracts. Inhal Toxicol 2013 0.76
158 Route-specific differences in distribution characteristics of octamethylcyclotetrasiloxane in rats: analysis using PBPK models. Toxicol Sci 2003 0.76
159 Deriving an explicit hepatic clearance equation accounting for plasma protein binding and hepatocellular uptake. Toxicol In Vitro 2012 0.75
160 Water pollutant fingerprinting tracks recent industrial transfer from coastal to inland China: a case study. Sci Rep 2013 0.75
161 Further comments on the bioavailability of D4. Environ Health Perspect 2002 0.75
162 Cross-species transcriptomic analysis of mouse and rat lung exposed to chloroprene. Toxicol Sci 2012 0.75
163 Inhalation dosimetry modeling with decamethylcyclopentasiloxane in rats and humans. Toxicol Sci 2008 0.75
164 Thresholds of carcinogenicity in the ED01 study. Toxicol Sci 2003 0.75
165 Prenatal PCB-153 Exposure and Decreased Birth Weight: Verner et al. Respond. Environ Health Perspect 2014 0.75
166 Comparing respiratory-tract and hepatic exposure-dose relationships for metabolized inhaled vapors: a pharmacokinetic analysis. Inhal Toxicol 2002 0.75
167 Liquid-air partition coefficients of 1,1-difluoroethane (HFC152a), 1,1,1-trifluoroethane (HFC143a), 1,1,1,2-tetrafluoroethane (HFC134a), 1,1,1,2,2-pentafluoroethane (HFC125) and 1,1,1,3,3-pentafluoropropane (HFC245fa). J Appl Toxicol 2010 0.75
168 Pitfalls and related improvements of in vivo gas uptake pharmacokinetic experimental systems. Inhal Toxicol 2005 0.75
169 Dose-incidence relationships derived from superposition of distributions of individual susceptibility on mechanism-based dose responses for biological effects. Toxicol Sci 2005 0.75
170 Erratum: Genetic variability in a frozen batch of MCF-7 cells invisible in routine authentication affecting cell function. Sci Rep 2016 0.75
171 In utero exposure to chloroquine alters sexual development in the male fetal rat. Toxicol Appl Pharmacol 2009 0.75
172 Refined PBPK model of aggregate exposure to methyl tertiary-butyl ether. Toxicol Lett 2007 0.75
173 Development of a physiologically based pharmacokinetic model for volatile fractions of gasoline using chemical lumping analysis. Environ Sci Technol 2004 0.75
174 Application of a multi-route physiologically based pharmacokinetic model for manganese to evaluate dose-dependent neurological effects in monkeys. Toxicol Sci 2012 0.75
175 Probing the control elements of the CYP1A1 switching module in H4IIE hepatoma cells. Toxicol Sci 2005 0.75